Tsz Him Hui1, Robyn L McClelland2, Matthew A Allison3, Carlos J Rodriguez4, Richard A Kronmal2, Susan R Heckbert5, Erin D Michos6, Philip J Barter1, Kerry-Anne Rye1, Kwok Leung Ong7. 1. Lipid Research Group, School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia. 2. Department of Biostatistics, University of Washington, Seattle, WA, USA. 3. Department of Family Medicine and Public Health, University of California San Diego, La Jolla, CA, USA. 4. Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, NC, USA; Department of Medicine, Wake Forest University School of Medicine, Winston Salem, NC, USA. 5. Department of Epidemiology, Cardiovascular Health Research Unit, University of Washington, Seattle, WA, USA. 6. Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA; Division of Cardiology, Johns Hopkins School of Medicine, Baltimore, MD, USA. 7. Lipid Research Group, School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia. Electronic address: oklws@yahoo.com.hk.
Abstract
BACKGROUND AND AIMS: Elevated circulating levels of fibroblast growth factor 21 (FGF21) are associated with multiple cardiovascular disease (CVD) risk factors and incident events. Previous small cross-sectional studies, mainly in Chinese populations, have suggested FGF21 may play a role in the development of atrial fibrillation (AF). We therefore investigated the relationship of FGF21 levels with incident AF in participants free of clinically apparent CVD at baseline in a large, multi-ethnic cohort. METHODS: A total of 5729 participants of four major ethnic groups (Caucasian, African American, Hispanic American, and Chinese American) from the Multi-Ethnic Study of Atherosclerosis (MESA), who were free of AF and had plasma FGF21 levels measured by ELISA at the baseline exam, were included in the analysis. Participants were followed up for incident AF over a median period of 12.9 years. Cox proportional hazards regression analysis was used. RESULTS: Among the 5729 participants, 778 participants developed incident AF. Participants with incident AF had significantly higher baseline FGF21 levels than those without incident AF (median = 166.0 and 142.8 pg/mL, p < 0.001). After adjusting for possible confounders, including demographic, socioeconomic and lifestyle factors, traditional CVD risk factors and circulating inflammatory markers, higher baseline FGF21 levels did not predict incident AF over the follow up period. There was no effect modification by sex or ethnicity. CONCLUSIONS: Baseline FGF21 levels were not associated with the development of AF in an ethnically diverse population followed long-term. Our findings do not support an important role of FGF21 in AF development.
BACKGROUND AND AIMS: Elevated circulating levels of fibroblast growth factor 21 (FGF21) are associated with multiple cardiovascular disease (CVD) risk factors and incident events. Previous small cross-sectional studies, mainly in Chinese populations, have suggested FGF21 may play a role in the development of atrial fibrillation (AF). We therefore investigated the relationship of FGF21 levels with incident AF in participants free of clinically apparent CVD at baseline in a large, multi-ethnic cohort. METHODS: A total of 5729 participants of four major ethnic groups (Caucasian, African American, Hispanic American, and Chinese American) from the Multi-Ethnic Study of Atherosclerosis (MESA), who were free of AF and had plasma FGF21 levels measured by ELISA at the baseline exam, were included in the analysis. Participants were followed up for incident AF over a median period of 12.9 years. Cox proportional hazards regression analysis was used. RESULTS: Among the 5729 participants, 778 participants developed incident AF. Participants with incident AF had significantly higher baseline FGF21 levels than those without incident AF (median = 166.0 and 142.8 pg/mL, p < 0.001). After adjusting for possible confounders, including demographic, socioeconomic and lifestyle factors, traditional CVD risk factors and circulating inflammatory markers, higher baseline FGF21 levels did not predict incident AF over the follow up period. There was no effect modification by sex or ethnicity. CONCLUSIONS: Baseline FGF21 levels were not associated with the development of AF in an ethnically diverse population followed long-term. Our findings do not support an important role of FGF21 in AF development.
Authors: Shunsuke Natori; Shenghan Lai; J Paul Finn; Antoinette S Gomes; W Gregory Hundley; Michael Jerosch-Herold; Gregory Pearson; Shantanu Sinha; Andrew Arai; Joao A C Lima; David A Bluemke Journal: AJR Am J Roentgenol Date: 2006-06 Impact factor: 3.959
Authors: Eui-Young Choi; Hossein Bahrami; Colin O Wu; Philip Greenland; Mary Cushman; Lori B Daniels; Andre L C Almeida; Kihei Yoneyama; Anders Opdahl; Aditya Jain; Michael H Criqui; David Siscovick; Christine Darwin; Alan Maisel; David A Bluemke; Joao A C Lima Journal: Circ Heart Fail Date: 2012-10-02 Impact factor: 8.790
Authors: Alain G Bertoni; Melicia C Whitt-Glover; Hyoju Chung; Katherine Y Le; R Graham Barr; Mahadevappa Mahesh; Nancy S Jenny; Gregory L Burke; David R Jacobs Journal: Am J Epidemiol Date: 2008-12-15 Impact factor: 4.897
Authors: M Mraz; M Bartlova; Z Lacinova; D Michalsky; M Kasalicky; D Haluzikova; M Matoulek; I Dostalova; V Humenanska; M Haluzik Journal: Clin Endocrinol (Oxf) Date: 2008-12-11 Impact factor: 3.478
Authors: Abhishek Maan; Neal W Jorgensen; Moussa Mansour; Samuel Dudley; Nancy S Jenny; Christopher Defilippi; Moyses Szklo; Alvaro Alonso; Marwan M Refaat; Jeremy Ruskin; Susan R Heckbert; E Kevin Heist Journal: Pacing Clin Electrophysiol Date: 2016-12-02 Impact factor: 1.976
Authors: Shu Q Liu; Derek Roberts; Alexei Kharitonenkov; Brian Zhang; Samuel M Hanson; Yan Chun Li; Li-Qun Zhang; Yu H Wu Journal: Sci Rep Date: 2013-09-26 Impact factor: 4.379
Authors: Denise M S van Marion; Eva A H Lanters; Kennedy S Ramos; Jin Li; Marit Wiersma; Luciënne Baks-Te Bulte; Agnes J Q M Muskens; Eric Boersma; Natasja M S de Groot; Bianca J J M Brundel Journal: Cells Date: 2020-09-16 Impact factor: 6.600